Medical Advocates

HCV Infection/Disease
  Investigational Drugs
 
 
General Reports 
Alisporivir
ABT-493
ABT-530

Beclabuvir
BMS-790052l
BMS-961955
BMS-986094
Deleobuvir
Entry Inhibitors
Faldaprevir
Glecaprevir
GS-0938

GS-9256
GS-9857
GSK8853,
Mericitabine
Miravirsen    
Nitazoxanide
Pibrentasvir
Ravidasvir
Ruzasvir
Resiquimod
Samatasvir
Silymarin
 
TMC647055/
Uprifosbuvir
Velpatasvir
Vaniprevir
Viramidine



 





 

HCV Main Page Main New/Newsworthy  HCV Drugs Home Page      

Last Update:  July 15, 2017  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader


General Reports
 

      Journal Abstracts, Abstracts, and Commentaries 
 
 
FULL-TEXT ARTICLE
Cynaropicrin: A Comprehensive Research Review and Therapeutic Potential As an Anti-Hepatitis C Virus Agent.
Elsebai MF, Mocan A, Atanasov AG.
Front Pharmacol. 2016 Dec 8;7:472
Abstract

Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals
Colpitts CC, Baumert TF.
Hepatol Int. 2016 Apr 5
Abstract

Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.
De Clercq E.
Rev Med Virol
. 2015 Jun 4.
Abstract

New therapeutic strategies in HCV: second-generation protease inhibitors.
Clark VC, Peter JA, Nelson DR.

Liver Int
. 2013 Feb;33 Suppl 1:80-4. d..
Abstract

New therapeutic strategies in HCV: polymerase inhibitors.
Gerber L, Welzel TM, Zeuzem S.
Liver Int. 2013 Feb;33 Suppl 1:85-92.
Abstract

Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS
. 2011 Sep 3.
Abstract

FULL-TEXT PDF ARTICLE
Moving Beyond Interferon Alfa: Investigational Drugs for Hepatitis C Virus Infection.
Wyles DL.
Top HIV Med
. 2010 Oct/Nov;18(4):132-136.
Paper

NS5B RNA Dependent RNA Polymerase Inhibitors: The Promising Approach to Treat Hepatitis C Virus Infections.
Deore RR, Chern JW.
Curr Med Chem
. 2010 Sep 22
Abstract


Alisporivir
 

      Journal Papers, Abstracts, and Commentaries
 
  A pharmacokinetic - viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on hepatitis C virologic response.
Nguyen TH, Mentré F, Levi M, et al
Clin Pharmacol Ther. 2014 Aug 28
Abstract

Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
Xia B, Barve A, Heimbach T,T, et al
Eur J Pharm Sci. 2014 Jul 4;63C:103-112.
Abstract

The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance.
Chatterji U, Garcia-Rivera JA, Baugh J, et al
Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34.
Abstract

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
Guedj J, Yu J, Levi M, Li B, et al
Hepatology. 2014 May;59(5):1706-14.
Abstract

FULL-TEXT ARTICLE
Profile of alisporivir and its potential in the treatment of hepatitis C.
Gallay PA, Lin K.
Drug Des Devel Ther. 2013;7:105-15.
Paper

Update on alisporivir in treatment of viral hepatitis C.
Flisiak R, Jaroszewicz J, Flisiak I, Łapiński T.
Expert Opin Investig Drugs. 2012 Mar;21(3):375-82
Abstract

The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
Quarato G, D'Aprile A, Gavillet B,  et al
Hepatology. 2012 May;55(5):1333-43.
Abstract

FULL-TEXT ARTICLE
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
Coelmont L, Hanoulle X, Chatterji U, et al
PLoS One. 2010 Oct 27;5(10):e13687
Paper

FULL-TEXT ARTICLE
Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice.
Wissing ER, Millay DP, Vuagniaux G, Molkentin JD.
Neuromuscul Disord. 2010 Nov;20(11):753-60.
Paper


ABT-493
 

      Journal Papers, Abstracts, and Commentaries
 
  Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection.
Lawitz EJ, O'Riordan WD, Asatryan A, et al
Antimicrob Agents Chemother. 2015 Dec 28.
Abstract

ABT-530
 

      Journal Papers, Abstracts, and Commentaries
 
  High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection.
Poordad F, Landis CS, Asatryan A,  et al
Liver Int
.
2016 Jan 18.
Abstract

Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection.
Lawitz EJ, O'Riordan WD, Asatryan A, et al
Antimicrob Agents Chemother. 2015 Dec 28.
Abstract


Beclabuvir (BMS-791325)
 

      Journal Papers, Abstracts, and Commentaries
 
  Beclabuvir for the treatment of hepatitis C.
Gentile I, Zappulo E, Buonomo AR, et al
Expert Opin Investig Drugs
. 2015 Jul 9:1-11
Abstract

FULL-TEXT ARTICLE
Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase.
Rigat KL, Lu H, Wang YK, et al
J Biol Chem
. 2014 Oct 9.
Paper

A Randomized, Placebo-Controlled, Single Ascending Dose Study of BMS-791325, a Hepatitis C Virus NS5B Polymerase Inhibitor, in Genotype 1 Infection.
Sims K, Lemm J, Eley T, et al
Antimicrob Agents Chemother. 2014 Apr 14
Abstract

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase.
Lemm JA, Liu M, Gentles RG,  et al
Antimicrob Agents Chemother. 2014 Apr 14.
Abstract

     

BMS-7900521
 

      Journal Papers, Abstracts, and Commentaries

 

  Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Nettles RE, Gao M, Bifano M, et al
Hepatology. 2011 Aug 11
Abstract

Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: In Vitro and In Vivo correlations.
Fridell RA, Wang C, Sun JH,
Hepatology. 2011 Aug 1.
Abstract

A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma.
Jiang H, Zeng J, Deng Y,  et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 15;879(22):2064-72.

Abstract

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052
Fridell RA, Qiu D, Valera L, et al
J Virol. 2011 Jul;85(14):7312-20
Abstract

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein.
Lee C, Ma H, Hang JQ, et al
Virology. 2011 May 25;414(1):10-8.
Abstract

FULL-TEXT ARTICLE

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Fridell RA, Qiu D, Wang C, et al
Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50

Paper


BMS-986094
 

      Journal Papers, Abstracts, and Commentaries
 
 
Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase
Zheng BZ, D'Andrea SV, Hanumegowda U, et al
Bioorg Med Chem Lett. 2017 Jun 11
Abstract

BMS-961955
 

      Journal Papers, Abstracts, and Commentaries
 
 
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
Ahmad T, Yin P, Saffitz J, Pockros PJ, et al
Hepatology. 2014 Sep 24.
Abstract

Deleobuvir (BI 207127)
 

      Journal Papers, Abstracts, and Commentaries
 
 

Entry Inhibitors
 

      Journal Papers, Abstracts, and Commentaries
 
  Entry inhibitors and future treatment of hepatitis C.
Fofana I, Jilg N, Chung RT, Baumert TF.
Antiviral Res. 2014 Feb 10..
Abstract

New Perspectives in HCV Therapy: Entry Inhibitors.
Donia M, Cacopardo B, Libra M,  et al
Recent Pat Antiinfect Drug Discov
. 2010 May 24.

Abstract

Faldaprevir (BI 201335)
 

      Journal Papers, Abstracts, and Commentaries
 

 
FULL-TEXT ARTICLE
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Sarrazin C, Manns M, Calleja JL,et al

PLoS One. 2016 Dec 28;11(12):e0168544.
Paper

Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir.
Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T.
Mol Biosyst. 2016 Oct 12.
Abstract

Safety and efficacy of faldaprevir in combination with pegylated interferon alfa-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.
Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, et al
Hepatol Res. 2016 May 6.
Abstract

Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Zeuzem S, Mantry P, Soriano V,  et al
Eur J Gastroenterol Hepatol
. 2016 Apr 29
Abstract

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM, Asselah T, Dieterich D,  et al
Ann Hepatol
. 2016 May-Jun, 2016;15(3):333-349.
Abstract

Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J, Gießmann T, Lang B, et al
J Pharm Pharmacol. 2016 Mar 28.
Abstract

FULL-TEXT ARTICLE
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Asselah T, Zeuzem S, Soriano V,
 et al
PLoS One. 2015 Dec 9;10(12):e0144004.
Paper

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of HCV Genotype-1 Following Treatment with Faldaprevir plus Pegylated Interferon Alfa-2a and Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL, Scherer J, Ranga M, et al
Antimicrob Agents Chemother. 2015 Jul 20.
Abstract

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D, Nelson M, Soriano V,  et al
AIDS
. 2015 Mar 13;29(5):571-581.

Abstract

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P, Asselah T, Foster GR,  et al
J Hepatol. 2015 Jan 2. pii: S0168-8278(14)00953-2
Abstract

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-naïve Patients with Chronic Hepatitis C and Advanced Liver Fibrosis/Cirrhosis.
Zeuzem S, Soriano V, Asselah T,  et al
Antimicrob Agents Chemother
. 2014 Dec 15. pii: AAC.04383-14
Abstract

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
Joseph D, Rose P, Strelkowa N,  et al  

J Clin Pharmacol
. 2014 Oct 28.
Abstract

Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir.
Sabo JP, Kort J, Ballow C,  et al.
Clin Infect Dis
. 2014 Aug 4.
Abstract

SILEN-C3: A Phase 2 Randomized Trial with Faldaprevir plus PegIFN/Ribavirin in Treatment-naive HCV Genotype-1-infected Patients.
Dieterich D, Asselah T, Guyader D,  et al
Antimicrob Agents Chemother. 2014 Apr 7.
Abstract

Generating an In Vitro-In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac).
Ramsden D, Tweedie DJ, et al
Drug Metab Dispos. 2014 Mar;42(3):407-14.
Abstract

Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation.
Li Y, Zhou J, Ramsden D, T et al
Drug Metab Dispos. 2014 Mar;42(3):384-93.
Abstract

FULL-TEXT ARTICLE
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL, Triki I, Cartier M, et al
Antimicrob Agents Chemother. 2014 Feb;58(2):698-705.
Paper

Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Co-cultured Human Hepatocyte System, Hepatopac™
Ramsden D, Tweedie DJ, Chan TS,  et al
Drug Metab Dispos. 2013 Dec 23
Abstract

Baseline HCV NS3 Polymorphisms and their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir.
Berger KL, Triki I, Cartier M, et al
Antimicrob Agents Chemother. 2013 Nov 11
Abstract

Viral Resistance in Hepatitis C Genotype-1 Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple Rising-dose Study.
Berger KL, Lagacé L, Triki I,  et al
Antimicrob Agents Chemother
. 2013 Jul 22
Abstract

Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial.
Sulkowski MS, Asselah T, Lalezari J,  et al
Hepatology. 2013 Jan 28.
Abstract

FULL-TEXT ARTICLE
n vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Lagacé L, White PW, Bousquet C,  et al
Antimicrob Agents Chemother. 2012 Jan;56(1):569-72
Paper
 
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
Duan J, Yong CL, Garneau M, Amad M,  et al
Xenobiotica. 2012 Feb;42(2):164-72
Abstract
 
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Zeuzem S, Asselah T, Angus P,  et al
Gastroenterology. 2011 Dec;141(6):2047-55;
Abstract
 
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Manns MP, Bourlière M, Benhamou Y, et al
J Hepatol. 2011 Jun;54(6):1114-22.
Abstract
 
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
White PW, Llinàs-Brunet M,  et al
Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8
Abstract
 
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
Llinàs-Brunet M, Bailey MD, Goudreau N,  et al
J Med Chem. 2010 Sep 9;53(17):6466-76
Abstract

Glecaprevir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Lin CW, Dutta S, Zhao W,  et al
Eur J Drug Metab Pharmacokinet 2017 Jul 7

Abstract

GS-0938
 

     Journal Papers, Abstracts, and Commentaries


 
Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Guedj J, Pang PS, Denning J, Rodriguez-Torres M,  et al
Antivir Ther. 2014 Jan 24.
Abstract

Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Guedj J, Pang PS, Denning J, Rodriguez-Torres M,  et al
Antivir Ther. 2014 Jan 24.
Abstract

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
Lawitz EJ, Rodriguez-Torres M, Denning J,  et al
J Viral Hepat. 2013 Oct;20(10):699-707
Abstract


GS-9256
 

      Journal Papers, Abstracts, and Commentaries
 
  Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
Mo H, Hedskog C, Lawitz E,}
Antiviral Res
. 2017 Jan 26.
Abstract

GS-9857
 

      Journal Papers, Abstracts, and Commentaries
 
  GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Rodriguez-Torres M, Glass S, Hill J, et al
J Viral Hepat. 2016 Mar 9.
Abstract

GSK2336805
 

     Journal Papers, Abstracts, and Commentaries

  Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.
Walker J, Crosby R, Wang A,  et al
Antimicrob Agents Chemother. 2013 Oct 14.
Abstract

Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1.
Wilfret DA, Walker J, Adkison KK,et al
Antimicrob Agents Chemother. 2013 Oct;57(10):5037
Abstract

Echocardiogram Study To Evaluate the Effect of the Novel Hepatitis C Virus NS5A Inhibitor GSK2336805 on Cardiac Contractility in Healthy Subjects.
Wilfret DA, Adkison KK, Jones LA, et al
Antimicrob Agents Chemother. 2013 Oct;57(10):5141-
Abstract

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 When Given as Monotherapy and in Combination With Peginterferon alfa-2a and Ribavirin in Hepatitis C Virus Genotype 1-infected Treatment-naive Subjects.
Gardner S, Cutrell A, Elko-Simms C,  et al
Liver Int. 2013 Sep 25.
Abstract


GSK8853
 

      Journal Papers, Abstracts, and Commentaries
 
  Preclinical characterization and in vivo efficacy of GSK8853, a small molecule inhibitor of the Hepatitis C virus NS4B protein.
Pouliot JJ, Thomson M, Xie M,  et al
Antimicrob Agents Chemother. 2015 Aug 10.
Abstract

Mericitabine
Mericitabine (RG7128)
 

      Journal Papers, Abstracts, and Commentaries
 
 

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
Chen YC, Bernaards C, Kulkarni R,  et al
Br J Clin Pharmacol. 2014 Mar 6.

Abstract

Intracellular Effects of the HCV Nucleoside Polymerase Inhibitor RO5885 (Mericitabine Parent) and Ribavirin in Combination.
Ma H, Le Pogam S, Fletcher S, et al
Antimicrob Agents Chemother. 2014 Feb 18.
Abstract

FULL-TEXT ARTICLE
Single-dose Pharmacokinetics of the HCV Polymerase Inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects.
Washington C, Moreira S, Haznedar J,  et al
Drug Metab Pharmacokinet. 2013 Sep 10.

Paper

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Wedemeyer H, Jensen D, Herring R Jr,  et al
Hepatology
. 2013 Aug;58(2):524-37.
Abstract

FULL-TEXT ARTICLE
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine
and the NS3/4 protease inhibitor danoprevir.

Le Pogam S, Yan JM, Chhabra M,  et al
Antimicrob Agents Chemother
. 2012 Nov;56(11):5494-502.

Paper

Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Pawlotsky JM, Najera I, Jacobson I.
Antivir Ther. 2012;17(3):411-23.
Abstract

FULL-TEXT ARTICLE
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Guedj J, Dahari H, Shudo E,  et al
Hepatology
. 2012 Apr;55(4):1030-7.
Paper

FULL-TEXT ARTICLE
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication
and selection of resistant variants in HCV-infected patients.

Le Pogam S, Seshaadri A, Ewing A, et al
J Infect Dis. 2010 Nov 15;202(10):1510-9.
Paper

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA,  et al
Lancet. 2010 Oct 30;376(9751):1467-75
Abstract


Miravirsen(SPC3649) 
 

      Journal Papers, Abstracts, and Commentaries
 
  Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
v
an der Ree MH, van der Meer AJ, van Nuenen AC, et al
Aliment Pharmacol Ther. 2015 Oct 26.
Abstract

FULL-TEXT ARTICLE
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.
Gebert LF, Rebhan MA, Crivelli SE, et al
Nucleic Acids Res. 2014 Jan;42(1):609-21
Paper


Pibrentasvir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Lin CW, Dutta S, Zhao W,  et al
Eur J Drug Metab Pharmacokinet 2017 Jul 7

Abstract

Ravidsavir
 

      Journal Papers, Abstracts, and Commentaries
 
  A new potent NS5A inhibitor in the management of hepatitis C virus: ravidasvir.
Hafez E, Elbaz T, Kassas ME, Esmat G.
Curr Drug Discov Technol. 2017 Jul 13.

Abstract

Resiquimod
 

      Journal Papers, Abstracts, and Commentaries
 
  Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
Pockros PJ, Guyader D, Patton H, Tong MJ, et al
J Hepatol. 2007 May 4;

Abstract

Ruzasvir
 

      Journal Papers, Abstracts, and Commentaries
 
  Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
Wyles D, Wedemeyer H, Ben-Ari Z, et al
Hepatology. 2017 Jul 7

Abstract

Samatasvir
 

      Journal Papers, Abstracts, and Commentaries
 
  In vitro Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus.
Bilello JP, Lallos LB, McCarville JF,  et al
Antimicrob Agents Chemother. 2014 May 27.
Abstract

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
Vince B, Hill JM, Lawitz EJ,  et al
J Hepatol. 2014 Jan 13
Abstract


TMC647055
 

      Journal Papers, Abstracts, and Commentaries
 
 

Velpatasvir
 

      Journal Papers, Abstracts, and Commentaries
 
 

Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C.
Voaklander R, Jacobson IM.
Expert Rev Gastroenterol Hepatol
. 2017 Jul 4.
Abstract

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Bourlière M, Gordon SC, Flamm SL, et al
N Engl J Med
. 2017 Jun 1;376(22):2134-2146

Abstract

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic HCV NS5A Inhibitor, in Healthy Subjects.
Mogalian E, German P, Kearney BP, et al
Antimicrob Agents Chemother. 2017 Feb 13.
Abstract

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
Brieva T, Rivero A, Rivero-Juarez A.
Expert Opin Drug Metab Toxicol. 2017 Feb
Abstract

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Greig SL.
Drugs. 2016 Oct 11.
Abstract

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Feld JJ, Jacobson IM, Hézode C,  et al
N Engl J Med. 2015 Nov 16.
Abstract

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S, Flamm SL, Shiffman ML,  et al 
Ann Intern Med. 2015 Nov 10.
Abstract


Uprifosbuvir
 

      Journal Papers, Abstracts, and Commentaries
 
  Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
Wyles D, Wedemeyer H, Ben-Ari Z, et al
Hepatology. 2017 Jul 7

Abstract

Vaniprevir (MK-7009)
 

      Journal Papers, Abstracts, and Commentaries
 
  Abstract

Characterization of Vaniprevir, a Hepatitis C Virus NS3/4A Protease Inhibitor, in Patients With HCV Genotype 1 Infection: Safety, Antiviral Activity, Resistance, and Pharmacokinetics.
Lawitz E, Sulkowski M, Jacobson I,  et al
Antiviral Res. 2013 Jun 6
Abstract

Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network and Substrate Envelope Analysis.
Xue W, Ban Y, Liu H, Yao X.
J Chem Inf Model. 2013 Jun 9.
Abstract

A phase 2B study of MK-7009 (Vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
Lawitz E, Rodriguez-Torres M, Stoehr A,  et al
J Hepatol. 2013 Feb 21.
Abstract

Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
Kong J, Chen CY, Balsells-Padros J,  et al
J Org Chem. 2012 Apr 20;77(8):3820-8
Abstract

Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.
Song ZJ, Tellers DM, Journet M,  et al
J Org Chem. 2011 Oct 7;76(19):7804-15.
Abstract
 
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
McCauley JA, McIntyre CJ, Rudd MT,  et al
J Med Chem. 2010 Mar 25;53(6):2443-63
Abstract

FULL-TEXT ARTICLE
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
Liverton NJ, Carroll SS, Dimuzio J,  et al
Antimicrob Agents Chemother. 2010 Jan;54(1):305-11.
Paper

Effect of disease state on ionization during bioanalysis of MK-7009, a selective HCV NS3/NS4 protease inhibitor, in human plasma and human Tween-treated urine by high-performance liquid chromatography with tandem mass spectrometric detection.
Anderson MD, Breidinger SA, Woolf E
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1047-56
Abstract

 


Voxilaprevir
 

      Journal Papers, Abstracts, and Commentaries
 
 
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Bourlière M, Gordon SC, Flamm SL, et al
 
N Engl J Med. 2017 Jun 1;376(22):2134-2146

Abstract


HCV Main Page Main New/Newsworthy  HCV Drugs Home Page      

HCV Investigational Drugs

   Pibrentasvir